Section Arrow
Quote
SION.NASDAQ
- Sionna Therapeutics Inc
Quotes are at least 15-min delayed:2026/03/06 18:10 EST
After Hours
Last
 35.93
0 (0.00%)
Bid
14.19
Ask
56.75
High 35.93 
Low 35.93 
Volume 2.40K 
Regular Hours (Closed)
Last
 35.93
+1.17 (+3.37%)
Day High 
36.225 
Prev. Close
34.76 
1-M High
39.865 
Volume 
310.44K 
Bid
14.19
Ask
56.75
Day Low
32.77 
Open
32.85 
1-M Low
32.565 
Market Cap 
1.55B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 35.86 
20-SMA 36.48 
50-SMA 39.29 
52-W High 45 
52-W Low 7.255 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.80/-2.03
Enterprise Value
1.56B
Balance Sheet
Book Value Per Share
7.21
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
IOVAIovance Biotherapeutics5.135+0.54+11.75%-- 
After Hours 5.16 +0.025 +0.49%
EDSAEdesa Biotech6.53+2.92+80.89%-- 
After Hours 6.8 +0.27 +4.13%
QNCXQuince Therapeutics0.1023-0.0025-2.39%-- 
After Hours 0.1013 -0.001 -0.98%
IBRXImmunityBio8.65-0.3001-3.35%-- 
After Hours 8.6604 +0.0104 +0.12%
QUREuniQure NV14.24+3.61+33.96%-- 
After Hours 23 +8.76 +61.52%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.